| The reason of the increase (decrease) in the net profit during the current quarter compared to the same quarter of the last year is | Net profit increases in general due to:1. Increase in sales in the following sectors:a. Pharmaceuticalsb. Specialty chemical2. Decrease in other expenses in pharmaceuticals sector.3. Decrease in provision for impairment of financial assets in pharmaceuticals sector.While noting that there is increase in selling and distribution expenses and general and administrative expenses in pharmaceuticals sector. |
| The reason of the increase (decrease) in the net profit during the current quarter compared to the previous period of the current year is | Net profit increases in general due to:1. Increase in sales and gross profit in the following sectors:a. Pharmaceuticalsb. Specialty chemical2. Decrease in other expenses in pharmaceuticals sector.While noting that there is increase in selling and distribution expenses in pharmaceuticals sector and increase in provision for impairment of financial assets in pharmaceuticals and specialty chemical sectors. |
| Statement of the type of external auditor’s report | Unmodified conclusion |
| Reclassification of Comparison Items | Certain comparative figures for the previous period have been reclassified to be consistent with the presentation of the current period. |
| Additional Information | 1. Net Shareholders’ Equity at the end of the period was SR1,579,544,902/- compared to SR1,421,009,316/- at the end of the similar period last year with an increase of 11%.2. With the completion of the sale of Al Anmaa subsequent to 31st March 2022, the financial results and statements of Al Tanmiya were accounted for in accordance with IFRS requirements. Please refer to Note 13 of the condensed consolidated interim financial statements for further details. |
